A Case Series of Spontaneous Pneumomediastinum With/Without Pneumothorax in COVID-19

Abstract

With the previous worldwide initial coronavirus disease 2019 (COVID-19) pandemic, a notable rise in spontaneous pneumomediastinum with/without pneumothorax (SPP) has been noted. Most cases were initially reported as complications secondary to barotrauma from mechanical ventilation (MV) with COVID-19. However, with the Delta strain, starting from December 2020, there have been multiple reports of SPP. The SPP is an uncommon complication outside use of assisted ventilation with either noninvasive positive pressure ventilation (NIPPV) or MV. COVID-19 has been linked to higher incidence of SPP without use of NIPPV or MV. We present a series of 5 cases with a polymerase chain reaction–confirmed COVID-19 diagnostic testing whose hospital course was complicated by SPP unrelated to the use of either NIPPV or MV.

Keywords

pneumomediastinum pneumothorax pulmonary critical care COVID-19

Introduction

Spontaneous pneumomediastinum with/without pneumothorax (SPP) is an uncommon complication outside the use of assisted ventilation with noninvasive positive pressure ventilation (NIPPV) and mechanical ventilation (MV) with a prevalence of 0.002%.^1-3 During the coronavirus disease 2019 (COVID-19) pandemic, there has been an increase in SPP, most seen with the Delta strain.¹

Pulmonary barotrauma results in air leakage due to wall rupture of marginal pulmonary alveoli from high intra-alveolar pressure usually due to artificial positive pressure ventilation, forceful coughing, vagal maneuvers, or straining.⁴ The SPP is described as free air or gas in the mediastinum and/or pleural space that is not caused by chest trauma.⁴ Barotrauma commonly occurs with positive pressure ventilation, however, is less common with use of high flow oxygen through nasal canula.⁴

Case Descriptions

In this section, we will present individual case descriptions. Please note that all patients were initially managed with conservative measures which are oxygen supplementation, dexamethasone 10 mg intravenously,⁵ baricitinib 4 mg by mouth once daily, Remdesivir, and self-proning as tolerated. In addition, all patients were admitted from the emergency department (ED), had positive COVID polymerase chain reaction (PCR) test, and managed initially in a step-down unit. Table 1 summarizes important clinical data points.

Table 1.

Summarization of Cases.

No. of patient	Demographic (age/sex/race)	Relevant medical history	Oxygen delivery method	Day of development of SPP from onset of HHFNC use	Management of SPP in the hospital	Patient outcome	Smoking status	Admission CRP
1	60/M/Hispanic	Diabetes, CVA	HHFNC 60 L/m 100% FiO2	7	Conservative, followed by chest tube	Worsened	Never	8.82 mg/dL
2	35/M/Hispanic	Obesity	HHFNC 55 L/m at 80% FiO2	4	Conservative	Improved	Smoker	4.34 mg/dL
3	54/M/Hispanic	Obesity, gastric cancer	HHFNC 45 L/m at 55% FiO2	8	Conservative	Improved	Never	5.24 mg/dL
4	28/M/Hispanic	Obesity	HHFNC 55 L/m at 100% FiO2	4	Conservative	Improved	Never	11.8 mg/dL
5	38/F/White	Alpha-1 antitrypsin deficiency, obesity	HHFNC 50 L/m at 100% FiO2	9	Conservative	Improved	Never	5.39 mg/dL

Abbreviations: SPP, spontaneous pneumomediastinum with/without pneumothorax; HHFNC, heated high-flow oxygen via nasal cannula; CVA, cerebrovascular accident; CRP, C-reactive protein.

Case 1

A 60-year-old man with medical history significant for diabetes mellitus, gastroesophageal reflux disease, no prior tobacco use and cerebrovascular accident, was admitted to the hospital for acute hypoxic respiratory failure secondary to COVID-19 pneumonia. He was diagnosed with COVID-19 infection 6 days prior to presentation. He was not vaccinated against COVID-19. On admission, he was requiring 100% fraction of inspired oxygen (FiO2) through heated high-flow oxygen via nasal cannula (HHFNC) at 60 L/m. C-reactive protein (CRP) was 8.82 mg/dL (range 0.00-0.30 mg/dL), d-dimer was 2342 ng/mL (range 0-529 ng/mL). Seven days after admission, patient developed asymptomatic pneumomediastinum with subcutaneous air followed by subsequent development of pneumothorax (Figure 1). However, his oxygenation worsened which required intubation and MV on day 13. He was diagnosed with severe acute respiratory distress syndrome (ARDS) with a PaO2:FiO2 ratio of 55. Positive pressure from MV subsequently worsened his pneumothorax so a chest tube was placed on day 17. He remained hypoxic requiring 100% FIO2 till day 37, when comfort measures were pursued at the family’s request. He expired shortly after compassionate extubation and withdrawal of MV.

Figure 1.

Computed tomography chest showing spontaneous pneumomediastinum with/without pneumothorax in patient 1.

Case 2

A 35-year-old man with medical history significant for obesity and 10-pack-year smoking history was admitted to the hospital for a 10-day history of worsening shortness of breath after he had been diagnosed with COVID-19. Chest x-ray (CXR) showed bilateral infiltrates and patient was requiring up to 3 L of oxygen through nasal canula. He was not vaccinated against COVID-19. On admission, CRP was 4.34 mg/dL and d-dimer was 758 ng/mL. He was subsequently started on HHFNC 55 L/m at 80% FiO2 due to worsening hypoxia on the day of admission. He developed pneumomediastinum, seen on computed tomography pulmonary angiography (CTPA) on day 4 of admission which remained stable (Figure 2). Oxygenation improved on day 11 when he was able to tolerate low-flow oxygen. On day 14 of admission, the patient developed right-sided pneumothorax which was small and did not necessitate chest tube placement. The patient recovered and was discharged home on home oxygen 3 L on day 27.

Figure 2.

Patient 2: spontaneous pneumomediastinum diagnosed with computed tomography chest.

Case 3

A 54-year-old man with a past medical history significant for obesity, gastric cancer with resection and adjuvant chemotherapy 10 years prior (in remission), and no prior tobacco use presented to the ED for worsening shortness of breath requiring 5 L of oxygen. He was not vaccinated against COVID-19. Initial CXR showed bilateral infiltrates consistent with COVID-19 pneumonia. His COVID-19 PCR was subsequently positive. He required HHFNC 45 L/m at 55% FiO2 shortly after admission. C-reactive protein was 5.24 mg/dL and d-dimer was 570 ng/mL. On day 8, the patient developed spontaneous pneumomediastinum on CXR with subsequent subcutaneous emphysema in the neck. Chest CT done on day 9 confirmed the pneumomediastinum present with subcutaneous air in the soft tissues of the neck (Figures 3 and 4). He was switched to low-flow oxygen on day 10. Chest x-ray done 12 days after admission showed trace right apical pneumothorax not requiring chest tube placement. The patient subsequently improved and was discharged home with home oxygen 3 L after 14 days of admission.

Figure 3.

Chest computed tomography demonstrating subcutaneous emphysema in the neck.

Figure 4.

Chest computed tomography demonstrating extensive pneumomediastinum.

Case 4

A 28-year-old obese man with no prior tobacco use presented to the ED with headache and nausea after he was diagnosed with COVID-19 at an outpatient clinic where a CXR showed bilateral infiltrates. The patient was started on 2 L of nasal cannula due to persistent hypoxia. He was not vaccinated against COVID-19. The CTPA on admission was negative for any pulmonary embolus, pneumothorax, or pneumomediastinum but showed multifocal ground-glass infiltrates consistent with COVID-19. Patient was begun on HHFNC on day 2 of admission. C-reactive protein was 11.8 mg/dL, d-dimer was 2195 ng/mL 2 days after admission. On day 6 of admission, due to new onset and worsening chest pain, chest CT was obtained which revealed pneumomediastinum with subcutaneous emphysema extending into the tissues of the neck (Figures 5 –7). His oxygenation did not worsen and was subsequently switched to low-flow nasal cannula. The pneumomediastinum resolved on day 10 of admission. He was discharged home with home oxygen after 13 days inpatient.

Figure 5.

Patient 4: extensive subcutaneous emphysema in the neck.

Figure 6.

Chest computed tomography again showing extensive subcutaneous emphysema in patient 4.

Figure 7.

Chest computed tomography showing pneumomediastinum in patient 4.

Case 5

A 38-year-old woman with a past medical history of alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, diabetes mellitus type II, obesity, chronic migraine headaches, and no prior tobacco use presented to ED 8 days after testing positive for COVID-19 experiencing worsening shortness of breath, fevers, and body aches. The patient had received casirivimab-imdevimab infusion but was noted to have SaO2 of 80% on 4 L nasal cannula. She was not vaccinated against COVID-19. She was subsequently placed on HHFNC 50 L/m at 100% FiO2 and admitted to the hospital. The CTPA showed diffuse bilateral ground-glass opacities intermixed with areas of consolidation and air bronchograms with several prominent right paratracheal lymph nodes. There was no evidence of pulmonary embolism, pneumothorax, or pneumomediastinum. Admission d-dimer was 1093 ng/mL, and CRP was 5.39 mg/dL. Day 9: she was transitioned to low-flow nasal cannula at 6 L, and a new pneumomediastinum with subcutaneous emphysema was seen in CXR obtained secondary to new complaint of chest pain (Figure 8). There was also a suggestion of trace right apical pneumothorax, not requiring chest tube placement. The SPP remained stable until her discharge after 16 days of admission. She was subsequently discharged home with home oxygen on 4 L.

Figure 8.

Chest x-ray demonstrating extensive subcutaneous emphysema of the chest wall and pneumomediastinum.

Discussion

This case series represent SPP without use of NIPPV or MV in HCA West Florida Brandon hospital during the Delta variant strain of COVID-19 spread in the United States. Noncompliant lungs in the face of miniscule pressure can develop spontaneous pneumothorax/pneumomediastinum in COVID-19 ARDS as suggested by Lemmers et al.⁶ In his study, there was no difference among incidence of barotrauma in patients mechanically ventilated using low tidal volume ventilation and low pressure defined as plateau pressures 23 ± 4 cmH2O. This population of patients does not necessarily reflect our patient population as these patients have been on HHFNC which at near maximum inspiratory flow induces a mean ± SD airway pressures at 30, 40, and 50 L/min were 1.93 ± 1.25 cm H(2)O, 2.58 ± 1.54 cm H(2)O, and 3.31 ± 1.05 cm H(2)O, respectively. However, our HHFNC goes up to 60 L of flow per minute. Other potential confounders are that our patients were using incentive spirometry as there have been case reports of patients using incentive spirometers causing pneumothorax/pneumomediastinum and a case of secondary spontaneous pneumothorax in patients receiving incentive spirometers with noncompliant lungs.^7-9 Incentive spirometer is used mostly in the postoperative setting to encourage long, deep breaths to prevent atelectasis and pneumonia which increases inspiratory volumes and promotes lung expansion.⁹ This has commonly become employed in COVID-19 ARDS as it has been proposed that the mechanism of action of incentive spirometry to improve ventilation/perfusion mismatch and alveolar-PaO2 gradient thus reducing the intrapulmonary shunting in which is proposed to happen in COVID-19 ARDS.¹⁰

Thus, it seems this could be a possible combination of factors such as frail noncompliant lungs and the combination of IS. Other possible contributors include oxygen toxicity from 100% FiO2 which results in free radicals causing endothelial damage with resultant increased adhesiveness and accumulation of neutrophils in the alveolar space with subsequent collagen deposition.¹¹ It is also believed that HHFNC generates a small amount of positive end expiratory pressure.^12,13 All these factors combined would theoretically increase the chances of barotrauma; in addition to COVID-19 alveolar damage. Tobacco smoking was not an important risk for developing SPP in our patients’ cohort.

Pneumomediastinum complicating COVID-19 has been treated conservatively, even with small pneumothorax, in prior case reports.¹⁴ The decision to place a chest tube has been an individual one, baring into consideration severity of the disease and expansion of pneumothorax with little extra guidance from prior published guidelines in spontaneous secondary disease.¹⁵

Mortality from pneumomediastinum is mostly related to the underlying etiology and treatment is usually geared toward associated pneumothoraces.¹⁶ Morbidity from pneumomediastinum is difficult to quantify. Possible contributing factors to increased morbidity are increased pain (as in our cases), increased monitoring time, thus increasing hospital length of stay, increased cost of care, days lost of work, and stress/cost of follow-up imaging and health care contact time. Pneumothorax has been shown to double mortality related to COVID-19.¹⁷ This significant (and independent) risk of death also contributed to mortality in patients on MV in the same study. Another interesting finding is that most patients developed SPP before MV or noninvasive ventilation, which has been replicated in other studies.¹⁷ Larger and longer-term follow-up studies are needed to examine whether SPP confers an increased risk for future pleural disease in patients with COVID-19.

We reported a unique finding of SPP in our patients receiving HHFNC, with relevant clinical data and radiological images. We have also reported laboratory data, clinical trajectory, and any interventions needed. There are several limitations to our study other than its inherent limitation of being retrospective; mainly the potential overestimation of smoking effect, vaccination status, and treatment offered. Another limitation is the possible missed cases of SPP as some cases were diagnosed incidentally. Furthermore, we could not confidently rule out prior undiagnosed lung disease in our cohort. With all these limitations, we think our study highlights the importance of SPP in COVID-19 patients, its clinical description, radiological features, expected recovery, and potential areas of further research.

Conclusion

The SPP seems to have a temporal relation with HHFNC in COVID-19 patients at our institution, occurring more frequently with the Delta strain. This may be due oxygen toxicity, severity of inflammation, use of IS, or small positive pressure generated by HHFNC. No specific treatment is available for SPP short of conservative measures. Further high-quality studies are needed to address the relationship between HHFNC and SPP, and how would that affect long-term incidence of pleural disease.

Footnotes

Acknowledgements

We want to thank the patient for allowing us to share this with the medical literature.

Authors’ Note

This case was submitted as a poster to Florida ACP.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from the patient for their anonymized information to be published in the article.

ORCID iDs

Crosby James

Subramanya Shyam Ganti

References

Brogna

Bignardi

Salvatore

, et al. Unusual presentations of COVID-19 pneumonia on CT scans with spontaneous pneumomediastinum and loculated pneumothorax: a report of two cases and a review of the literature. Heart Lung. 2020;49(6): 864-868.

Marza

Petrica

Lungeanu

, et al. Risk factors, characteristics, and outcome in non-ventilated patients with spontaneous pneumothorax or pneumomediastinum associated with SARS-CoV-2 infection. Int J Gen Med. 2022;15:489-500. doi:10.2147/IJGM.S347178

Shaikh

Al Ameri

Shaheen

, et al. Spontaneous pneumomediastinum and pneumothorax in COVID-19 patients: a tertiary care experience. Health Sci Rep. 2021;4(3):e339. doi:10.1002/hsr2.339

Murayama

Gibo

Spontaneous pneumomediastinum and Macklin effect: overview and appearance on computed tomography. World J Radiol. 2014;6(11):850-854. doi:10.4329/wjr.v6.i11.850

Villar

Ferrando

Martínez

, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276. doi:10.1016/S2213-2600(19)30417-5

Lemmers

DHL

Abu Hilal

Bnà

, et al. Pneumomediastinum and subcutaneous emphysema in COVID-19: barotrauma or lung frailty? ERJ Open Res. 2020;6(4):00385-02020. doi:10.1183/23120541.00385-2020

Pribadi

Singh

Rumende

CM.

The role of incentive spirometry in primary spontaneous pneumothorax. Acta Med Indones. 2016;48(1):54-57.

Liu

Hudey

Hill

Take my breath away: a case of secondary pneumothorax caused by incentive spirometer use in the setting of necrotizing pneumonia. Chest J. 2018;154(4):699A. doi:10.1016/j.chest.2018.08.633

Kenny

Kuschner

WG.

Pneumothorax caused by aggressive use of an incentive spirometer in a patient with emphysema. Respir Care. 2013;58(7):e77-e79. doi:10.4187/respcare.02130

10.

Bime

Fiero

, et al. High positive end-expiratory pressure is associated with improved survival in obese patients with acute respiratory distress syndrome. Am J Med. 2017; 130(2):207-213. doi:10.1016/j.amjmed.2016.09.029

11.

Mach

Thimmesch

Pierce

JD.

Consequences of hyperoxia and the toxicity of oxygen in the lung. Nurs Res Pract. 2011;2011:260482. doi:10.1155/2011/260482

12.

Groves

Tobin

High flow nasal oxygen generates positive airway pressure in adult volunteers. Aust Crit Care. 2007;20(4): 126-131.

13.

Parke

Eccleston

McGuinness

SP.

The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011;56(8):1151-1155. doi:10.4187/respcare.01106

14.

Zendah

Bacha

Daghfous

Ben M’rad

Merai

Tritar

Management of spontaneous pneumomediastinum in the adult: 14 cases and a review of the literature. Rev Pneumol Clin. 2010;66(3):163-166. doi:10.1016/j.pneumo.2009.08.003

15.

MacDuff

Arnold

Harvey

; BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(suppl 2):ii18-ii31. doi:10.1136/thx.2010.136986

16.

Iteen

Bianchi

Sharman

Pneumomediastinum In: StatPearls. Treasure Island, FL; 2022.

17.

Malik

Kaushik

Heidelman

, et al. Characteristics and factors associated with mortality in patients with coronavirus disease 2019 and pneumothorax. Mayo Clin Proc Innov Qual Outcomes. 2022;6(3):257-268.